BEDFORD, Mass. — February 13, 2026 — Leads & Copy — Ocular Therapeutix, Inc. (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026, at 8:00 AM ET to review topline results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for treating wet age-related macular degeneration (wet AMD).
The company announced the webcast today. Detailed data from the trial will be presented at the 49th Macula Society Annual Meeting between February 25–28, 2026.
AXPAXLI™, also known as OTX-TKI, is Ocular’s investigational product candidate for retinal disease. It is an axitinib intravitreal hydrogel based on the company’s ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. Currently, AXPAXLI is in Phase 3 clinical trials for wet AMD and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also includes DEXTENZA®, an FDA-approved corticosteroid for treating ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Additionally, the pipeline features OTX-TIC, a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for treating open-angle glaucoma or ocular hypertension. The company is currently evaluating next steps for the OTX-TIC program.
To register for the virtual webcast, click here. The live and archived webcast can be accessed on the Events and Presentations section of the Investor Relations page of the Ocular Therapeutix website. A replay will be archived for at least 30 days.
Ocular Therapeutix is an integrated biopharmaceutical company focused on redefining the retina experience.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Source: Ocular Therapeutix, Inc.
